AbbVie’s Inc (NYSE:ABBV) Investigational Regimen Of Gelcaprevir Pibrent Asvir (G/P) Has Been Approved For Review By Health Canada

AbbVie’s Inc (NYSE:ABBV) Investigational Regimen Of Gelcaprevir Pibrent Asvir (G/P) Has Been Approved For Review By Health Canada

It was announced today by AbbVie Inc. (NYSE:ABBV) that their New Drug Review, otherwise known as NDA has been approved for priority review by Health Canada. The drug itself, which was approved is the company’s self-developed investigational regimen of Glecaprevir/Pibrent Asvir (G/P). This drug was developed in order to provide a solution or cure for the treatment of major chronic hepatitis C virus (HCV) genotypes. This drug has been manufactured […]

Read More ˃